SepsiScan raises €50K from Commercialization Reactor
Latvian medtech SepsiScan has recently raised €50K from the Latvian Commercialization Reactor Seed Fund.
Founded in Riga in 2023 by Didzis Rutitis and Matiss Lacis, SepsiScan develops hyperspectral imaging devices that can be used for early diagnosis of sepsis. The company's solution can be applied in addition to the existing sepsis detection technologies in hospitals and military field environments.
SepsiScan's technology is based on optics. It uses software that can instantly analyze the visual information obtained, providing results in just a few minutes. This makes it faster than alternative solutions. Furthermore, the device is wireless and mobile.
SepsiScan is a spin-off company from the Institute of Atomic Physics and Spectroscopy at the University of Latvia. In 2023, it graduated from the 15th batch of the Latvian accelerator Buildit's and the 4th batch of the Estonian Health Founders accelerator.
Founded in 2009 by Nikolai Adamovitch, Commercialization Reactor Seed Fund offers a deeptech oriented acceleration program in Riga. It invests up to €50K at the pre-seed stage and offers up to €250K as a follow-on investment.
